EISAI CO., LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,735 JPY | -0.68% |
|
+1.45% | -4.50% |
| May. 24 | BioArctic, Eisai's Azlheimer’s Disease Drug Wins Regulatory Nod in South Korea | MT |
| May. 16 | Eisai's Attributable Profit Falls 23.5% in Fiscal 2024 | MT |
| Sales 2024 | 742B 4.73B | Sales 2025 * | 768B 4.9B | Capitalization | 1,945B 12.39B |
|---|---|---|---|---|---|
| Net income 2024 | 42.41B 270M | Net income 2025 * | 50.2B 320M | EV / Sales 2024 | 2.4 x |
| Net cash position 2024 * | 172B 1.1B | Net cash position 2025 * | 214B 1.36B | EV / Sales 2025 * | 2.25 x |
| P/E ratio 2024 |
42
x | P/E ratio 2025 * |
38.6
x | Employees | 11,076 |
| Yield 2024 |
2.57% | Yield 2025 * |
2.36% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
More news
| 1 day | -0.68% | ||
| 1 week | +1.45% | ||
| Current month | +3.58% | ||
| 1 month | +3.58% | ||
| 3 months | +6.63% | ||
| 6 months | -12.13% | ||
| Current year | -4.50% |
1 week
6 530.00
6 830.00
1 month
6 267.007 077.00
Current year
5 795.007 818.00
1 year
5 795.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
4 064.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 72 | 21-05-31 |
Hideki Hayashi
BRD | Director/Board Member | 66 | 81-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 19 M€ | +10.04% | ||
| 1.23% | 240 M€ | +17.47% | ||
| 1.13% | 28,258 M€ | +17.12% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 6,735 | -0.68% | 860 300 |
| 24-05-27 | 6,781 | +0.25% | 875,500 |
| 24-05-24 | 6,764 | +1.87% | 1,129,600 |
| 24-05-23 | 6,640 | +0.71% | 1,130,200 |
| 24-05-22 | 6,593 | -0.69% | 933,000 |
Delayed Quote Japan Exchange, May 28, 2024 at 02:00 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-11-05
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
6,781
JPY
Average target price
8,279
JPY
Spread / Average Target
+22.08%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -4.50% | 12.4B | |
| +38.51% | 727B | |
| +31.49% | 594B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +14.04% | 243B | |
| +8.12% | 205B | |
| -5.36% | 203B | |
| +6.19% | 164B |
- Stock Market
- Equities
- 4523 Stock
